{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Flow cytometry to detect tumor contamination.","groups":[{"description":"Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.\n\nFilgrastim: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days\n\nPlerixafor: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight\n\nApheresis: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 10\\^6 CD34+ cells/kg.","id":"OG000","title":"Hematopoietic Progenitor Cells (HPC)"}],"populationDescription":"Because no data from any participant was sufficiently collected to assess tumor cell contamination, we were not able to determine the effect of plerixafor on this parameter.","reportingStatus":"POSTED","timeFrame":"Day 1 of apheresis","title":"Impact of Plerixafor in the Degree of Tumor Cell Contamination in the Final Product","type":"SECONDARY"}